AI-generated analysis. Always verify with the original filing.
Alto Neuroscience, Inc. reported full year 2025 financial results, including net loss of $63.2 million compared to $61.4 million in 2024, and cash, cash equivalents, and restricted cash of $177 million as of December 31, 2025, expected to fund operations into 2028. The company provided business highlights on ALTO-207 acquisition for treatment-resistant depression and upcoming clinical trial milestones across its pipeline.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Alto Neuroscience, Inc. 104 Cover Page Interactive Data File (emb
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $45.60 | GAAP |
| General and administrative expenses | $20.70 | GAAP |
| Total operating expenses | $66.40 | GAAP |
| Net loss | $-63.20 | GAAP |
| Net loss per share attributable to common stockholders, basic and diluted | $-2.19 | GAAP |